185 related articles for article (PubMed ID: 18467314)
1. Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.
Knab BR; Salama JK; Solanki A; Stenson KM; Cohen EE; Witt ME; Haraf DJ; Vokes EE
Ann Oncol; 2008 Sep; 19(9):1650-4. PubMed ID: 18467314
[TBL] [Abstract][Full Text] [Related]
2. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion.
Worden FP; Moyer J; Lee JS; Taylor JM; Urba SG; Eisbruch A; Teknos TN; Chepeha DB; Prince ME; Hogikyan N; Lassig AA; Emerick K; Mukherji S; Hadjiski L; Tsien CI; Miller TH; Wallace NE; Mason HL; Bradford CR; Wolf GT
Laryngoscope; 2009 Aug; 119(8):1510-7. PubMed ID: 19504552
[TBL] [Abstract][Full Text] [Related]
3. Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience.
Nguyen-Tan PF; Le QT; Quivey JM; Singer M; Terris DJ; Goffinet DR; Fu KK
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1172-80. PubMed ID: 11483326
[TBL] [Abstract][Full Text] [Related]
4. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
Vokes EE; Stenson K; Rosen FR; Kies MS; Rademaker AW; Witt ME; Brockstein BE; List MA; Fung BB; Portugal L; Mittal BB; Pelzer H; Weichselbaum RR; Haraf DJ
J Clin Oncol; 2003 Jan; 21(2):320-6. PubMed ID: 12525525
[TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
Haraf DJ; Rosen FR; Stenson K; Argiris A; Mittal BB; Witt ME; Brockstein BE; List MA; Portugal L; Pelzer H; Weichselbaum RR; Vokes EE
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5936-43. PubMed ID: 14676118
[TBL] [Abstract][Full Text] [Related]
6. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
Posner MR; Norris CM; Wirth LJ; Shin DM; Cullen KJ; Winquist EW; Blajman CR; Mickiewicz EA; Frenette GP; Plinar LF; Cohen RB; Steinbrenner LM; Freue JM; Gorbunova VA; Tjulandin SA; Raez LE; Adkins DR; Tishler RB; Roessner MR; Haddad RI;
Ann Oncol; 2009 May; 20(5):921-7. PubMed ID: 19179556
[TBL] [Abstract][Full Text] [Related]
7. Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: the M. D. Anderson Cancer Center experience.
Shirinian MH; Weber RS; Lippman SM; Dimery IW; Earley CL; Garden AS; Michaelson J; Morrison WH; Kramer A; Byers R
Head Neck; 1994; 16(1):39-44. PubMed ID: 7510276
[TBL] [Abstract][Full Text] [Related]
8. Concurrent chemoradiotherapy for T4 patients with hypopharyngeal and laryngeal squamous cell carcinomas.
Nishimura G; Tsukuda M; Horiuchi C; Satake K; Yoshida T; Nagao J; Kawakami M; Kondo N; Arai Y; Taguchi T; Matsuda H; Mikami Y
Auris Nasus Larynx; 2007 Dec; 34(4):499-504. PubMed ID: 17604583
[TBL] [Abstract][Full Text] [Related]
9. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy.
Lefebvre JL; Rolland F; Tesselaar M; Bardet E; Leemans CR; Geoffrois L; Hupperets P; Barzan L; de Raucourt D; Chevalier D; Licitra L; Lunghi F; Stupp R; Lacombe D; Bogaerts J; Horiot JC; Bernier J; Vermorken JB; ;
J Natl Cancer Inst; 2009 Feb; 101(3):142-52. PubMed ID: 19176454
[TBL] [Abstract][Full Text] [Related]
10. Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer.
Mantz CA; Vokes EE; Kies MS; Mittal B; Witt ME; List MA; Weichselbaum RR; Haraf DJ
Ann Oncol; 2001 Mar; 12(3):343-7. PubMed ID: 11332146
[TBL] [Abstract][Full Text] [Related]
11. [Results of definitive radiotherapy for squamous cell carcinomas of the larynx patients with subglottic extension].
Lévy A; Blanchard P; Janot F; Temam S; Bourhis J; Daly-Schveitzer N; Tao Y
Cancer Radiother; 2014 Jan; 18(1):1-6. PubMed ID: 24309002
[TBL] [Abstract][Full Text] [Related]
12. Selection of therapeutic treatment with alternating chemoradiotherapy for larynx preservation in laryngeal carcinoma patients.
Ijichi K; Hanai N; Kawakita D; Ozawa T; Suzuki H; Hirakawa H; Kodaira T; Murakami S; Hasegawa Y
Jpn J Clin Oncol; 2014 Nov; 44(11):1063-9. PubMed ID: 25187666
[TBL] [Abstract][Full Text] [Related]
13. Use of concurrent chemoradiation in advanced staged (T4) laryngeal cancer.
Wick CC; Rezaee RP; Wang T; Garcia-Jarchow AM; Zender CA; Gibson M; Yao M; Lavertu P
Am J Otolaryngol; 2017; 38(1):72-76. PubMed ID: 27838151
[TBL] [Abstract][Full Text] [Related]
14. Role of concurrent chemoradiation in laryngeal preservation for supraglottic cancer.
Yoon TM; Lee JK; Cho JS; Lim SC; Chung WK
J Otolaryngol Head Neck Surg; 2010 Apr; 39(2):142-9. PubMed ID: 20211100
[TBL] [Abstract][Full Text] [Related]
15. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.
Salama JK; Stenson KM; Kistner EO; Mittal BB; Argiris A; Witt ME; Rosen F; Brockstein BE; Cohen EE; Haraf DJ; Vokes EE
Ann Oncol; 2008 Oct; 19(10):1787-94. PubMed ID: 18539617
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted partial larynx and/or carotid artery sparing modulated radiation therapy of glottic cancer.
Janssen S; Glanzmann C; Huber G; Studer G
Radiat Oncol; 2014 Jun; 9():136. PubMed ID: 24923417
[TBL] [Abstract][Full Text] [Related]
17. Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Janoray G; Pointreau Y; Garaud P; Chapet S; Alfonsi M; Sire C; Jadaud E; Calais G
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26681800
[TBL] [Abstract][Full Text] [Related]
18. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm.
Urba S; Wolf G; Eisbruch A; Worden F; Lee J; Bradford C; Teknos T; Chepeha D; Prince M; Hogikyan N; Taylor J
J Clin Oncol; 2006 Feb; 24(4):593-8. PubMed ID: 16380415
[TBL] [Abstract][Full Text] [Related]
19. Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Catala d'Oncologia in stage III larynx carcinoma.
Majem M; Mesia R; Mañós M; Gomez J; Galiana R; Cardenal F; Juan A; Montes A; Perez FJ; Nogues J; Llluch JR
Laryngoscope; 2006 Sep; 116(9):1651-6. PubMed ID: 16954998
[TBL] [Abstract][Full Text] [Related]
20. A single-institutional experience of 15 years of treating T3 laryngeal cancer with primary radiotherapy, with or without chemotherapy.
Al-Mamgani A; Tans L; van Rooij P; Levendag PC
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1000-6. PubMed ID: 22099030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
